BioXcel Therapeutics (BTAI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 65/100 (HIGH), 1.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 23.2% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- IGALMI — BTAI PDUFA 2026-11-14
Recent News & SEC Filings
- Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
- Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
- Teva makes stalking horse bid for BioXcel assets
- Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
- BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals
- BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates
- What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
- BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper. — NPP Digit Psychiatry Neurosci 2026 Sep 18 PMID 42760290
- Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder. — J Clin Psychiatry 2026 Sep 16 PMID 42752599
- Towards precision psychiatry: initial foundations and future directions. — Nat Rev Drug Discov 2026 Aug 24 PMID 42637870
- Effects of Brexpiprazole on Functioning in Patients With Schizophrenia Who Have Hostility and Agitation Symptoms: Post Hoc Analysis of Short- and Long-Term Trials. — J Clin Psychiatry 2026 Jul 20 PMID 42474330
- Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. — EBioMedicine 2026 Aug PMID 42468111
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for BioXcel Therapeutics.
Full BTAI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.